The Facilitator Training Manual on Workplace Pandemic Preparedness is a guide developed by GIZ and the Ministry of Health to help organizations prepare for and respond to pandemics while ensuring business continuity. It provides structured guidance on training, risk assessment, prevention, and respo...nse strategies for both medical and non-medical personnel.
Key topics include pandemic preparedness and response, covering diseases like Influenza, Cholera, Yellow Fever, and Meningitis, as well as personal hygiene, risk communication, and business continuity planning. The manual emphasizes participatory learning, practical training, and leadership in crisis management, aiming to enhance institutional resilience and ensure workplaces remain safe and operational during health crises.
more
Malaria is a prevalent cause of febrile illnesses in areas with high transmission, and its clinical presentation overlaps with initial signs of Ebola disease. For this reason, the effectiveness of the Ebola response in Guinea, Liberia and Sierra Leone can be optimized through the deployment of targe...ted measures to reduce the number of fever cases due to malaria
WHO recommends specific adaptations in the diagnosis of malaria and in LLIN distribution in countries heavily affected by the Ebola outbreak and mass drug administration using artemisinin-based combination therapies (ACTs) in areas where transmission of both Ebola and malaria is high and access to malaria treatment is very low.
more
Interim Guidance, published 11 January 2021.
The cold chain is necessary to prevent damage to vaccines caused by heat exposure. However, improper use of cold chain equipment may cause damage to freeze-sensitive vaccines (i.e. those vaccines containing alum adjuvant or oil-emulsion adjuvant). Studie...s conducted in several countries with hot and cold climates show frequent occurrences of sub-zero temperatures in the cold chain. The most common cause of exposure to freezing temperature is the failure to correctly condition ice packs prior to transport. Vaccines that are inadvertently frozen lose potency, increase wastage rates and increase the risk of adverse events following immunization (AEFI). Vaccine carriers protect vaccine potency during immunization sessions and transport to outreach sites. This guidance document is intended to help inform which type of vaccine carrier to select based on local context, to maintain vaccine quality, especially at service delivery points.
more
This annual report gives an overview of WHO lesotho Country office's undertakings and achievements in the context of an extraordinary health emergency. As we walk another mile this year, may we embrace all lessonst leanred in the previous year, learn from what did not work so well and take on new op...portunities in championing health in the country.
more
The Integrated Management of Adolescent/Adult Illness (IMAI) approach
In March 2020, the World Health Organization (WHO) declared that the outbreak of COVID-19, the disease caused by a new coronavirus, constituted a pandemic, given the speed and scale of its transmission. The Region of the Americas is characterized by its rich multi-ethnic and multicultural heritage. ...Nonetheless, indigenous peoples, Afro-descendants, and other ethnic groups are often subject to discrimination and exclusion, resulting in health inequities. COVID-19 may have a greater impact on certain populations, such as indigenous peoples and Afro-descendants.
more
Scientific Brief 9 July 2020
This document provides a decision-making framework for implementation of mass treatment interventions, active case-finding campaigns and population-based surveys for neglected tropical diseases in the context of the COVID-19 pandemic. A two-step approach is proposed: a risk–benefit assessment, to ...decide if the planned activity should proceed; and an examination of a list of precautionary measures that should be applied with the aim of decreasing the risk of transmission of COVID-19 associated with the activity, and strengthening the capacity of the health system to manage any residual risk. This guidance note is intended to health authorities, NTD programme managers and their supporting partners.
more